Sun BioPharma Reports Third Quarter 2016 Results and Provides Clinical Progress Update
Completed enrollment of second and third cohorts in Phase 1 clinical study of SBP-101; first-in-class proprietary compound designed specifically for pancreatic disease Uplisted to OTCQB and secured DTC eligibility MINNEAPOLIS, Nov. 10, 2016 (GLOBE NEWSWIRE …